Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol MRI for Pembrolizumab Response in NSCLC Brain Metastases
NCT03325166Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Nov 2017
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by OHSU Knight Cancer Institute. Started Nov 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03325166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325166.